Literature DB >> 15858149

c-kit Mutations in patients with childhood-onset mastocytosis and genotype-phenotype correlation.

Hirokatsu Yanagihori1, Noritaka Oyama, Koichiro Nakamura, Fumio Kaneko.   

Abstract

Mastocytosis represents a clonal proliferation of mast cell hematopoietic progenitors caused by gain-of-function mutations of the c-kit gene. The heterogeneity of c-kit mutations may have contributed to difficulties in characterizing genotype-phenotype correlation of the disease. Our goal was to analyze a set of reported pathogenic c-kit mutations in patients with childhood-onset cutaneous mastocytosis, in comparison with those with adult-onset disease, and to correlate these with clinical presentation. We performed polymerase chain reaction and direct sequencing using genomic DNA samples from 16 nonfamilial Japanese patients with indolent cutaneous mastocytosis (12 with childhood-onset disease and 4 with adult-onset disease) to look for the most common c-kit mutations at codons 816, 560, 820, and 839. A substantial number of patients had missense codon 816 mutations (10 of 12 in the childhood-onset group, 83.3%; and 4 of 4 in the adult-onset group, 100%). The most common mutation was Asp816Val (9 of 16, 64.3%) followed by Asp816Phe (5 of 16, 35.7%). Moreover, children with the Asp816Phe mutation developed cutaneous mastocytosis at an earlier age as compared to those with the Asp816Val mutation (mean age of onset, 1.3 months versus 5.9 months, respectively; P = 0.068). No other mutation variations were found in our cohort. In summary, we confirmed a high incidence of two distinct c-kit mutations, Asp816Val and Asp816Phe, in patients with childhood-onset cutaneous mastocytosis. Our results provide new insights into common c-kit mutations, which may contribute to different clinical courses of the disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15858149      PMCID: PMC1867517          DOI: 10.1016/S1525-1578(10)60552-1

Source DB:  PubMed          Journal:  J Mol Diagn        ISSN: 1525-1578            Impact factor:   5.568


  20 in total

1.  c-kit mutation in a population of patients with mastocytosis.

Authors:  H Nagata; T Okada; A S Worobec; T Semere; D D Metcalfe
Journal:  Int Arch Allergy Immunol       Date:  1997 May-Jul       Impact factor: 2.749

2.  Familial gastrointestinal stromal tumours with germline mutation of the KIT gene.

Authors:  T Nishida; S Hirota; M Taniguchi; K Hashimoto; K Isozaki; H Nakamura; Y Kanakura; T Tanaka; A Takabayashi; H Matsuda; Y Kitamura
Journal:  Nat Genet       Date:  1998-08       Impact factor: 38.330

Review 3.  The protooncogene c-kit and c-kit ligand in human disease.

Authors:  H Vliagoftis; A S Worobec; D D Metcalfe
Journal:  J Allergy Clin Immunol       Date:  1997-10       Impact factor: 10.793

4.  Classification and diagnosis of mastocytosis: current status.

Authors:  D D Metcalfe
Journal:  J Invest Dermatol       Date:  1991-03       Impact factor: 8.551

5.  A new c-kit mutation in a case of aggressive mast cell disease.

Authors:  J M Pignon; S Giraudier; P Duquesnoy; H Jouault; M Imbert; W Vainchenker; J P Vernant; M Tulliez
Journal:  Br J Haematol       Date:  1997-02       Impact factor: 6.998

6.  Clinical correlates of the presence of the Asp816Val c-kit mutation in the peripheral blood mononuclear cells of patients with mastocytosis.

Authors:  A S Worobec; T Semere; H Nagata; D D Metcalfe
Journal:  Cancer       Date:  1998-11-15       Impact factor: 6.860

7.  A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib.

Authors:  Cem Akin; Gerard Fumo; Akif S Yavuz; Peter E Lipsky; Len Neckers; Dean D Metcalfe
Journal:  Blood       Date:  2003-12-24       Impact factor: 22.113

8.  Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product.

Authors:  T Furitsu; T Tsujimura; T Tono; H Ikeda; H Kitayama; U Koshimizu; H Sugahara; J H Butterfield; L K Ashman; Y Kanayama
Journal:  J Clin Invest       Date:  1993-10       Impact factor: 14.808

Review 9.  Urticaria pigmentosa: a review of 67 pediatric cases.

Authors:  J M Azaña; A Torrelo; I G Mediero; A Zambrano
Journal:  Pediatr Dermatol       Date:  1994-06       Impact factor: 1.588

10.  KIT mutations are common in testicular seminomas.

Authors:  Kathleen Kemmer; Christopher L Corless; Jonathan A Fletcher; Laura McGreevey; Andrea Haley; Diana Griffith; Oscar W Cummings; Cecily Wait; Ajia Town; Michael C Heinrich
Journal:  Am J Pathol       Date:  2004-01       Impact factor: 4.307

View more
  10 in total

Review 1.  Systemic mast cell activation disease: the role of molecular genetic alterations in pathogenesis, heritability and diagnostics.

Authors:  Britta Haenisch; Markus M Nöthen; Gerhard J Molderings
Journal:  Immunology       Date:  2012-11       Impact factor: 7.397

2.  Allele-specific polymerase chain reaction for the imatinib-resistant KIT D816V and D816F mutations in mastocytosis and acute myelogenous leukemia.

Authors:  Christopher L Corless; Patina Harrell; Mario Lacouture; Troy Bainbridge; Claudia Le; Ken Gatter; Clifton White; Scott Granter; Michael C Heinrich
Journal:  J Mol Diagn       Date:  2006-11       Impact factor: 5.568

Review 3.  Diagnosis and treatment of cutaneous mastocytosis in children: practical recommendations.

Authors:  Mariana Castells; Dean D Metcalfe; Luis Escribano
Journal:  Am J Clin Dermatol       Date:  2011-08-01       Impact factor: 7.403

Review 4.  Cutaneous and systemic mastocytosis in children: a risk factor for anaphylaxis?

Authors:  A Matito; M Carter
Journal:  Curr Allergy Asthma Rep       Date:  2015-05       Impact factor: 4.806

Review 5.  Primary mast cell disorders in children.

Authors:  Ari J Fried; Cem Akin
Journal:  Curr Allergy Asthma Rep       Date:  2013-12       Impact factor: 4.806

6.  Proceedings from the Inaugural American Initiative in Mast Cell Diseases (AIM) Investigator Conference.

Authors:  Jason Gotlib; Tracy I George; Melody C Carter; K Frank Austen; Bruce Bochner; Daniel F Dwyer; Jonathan J Lyons; Matthew J Hamilton; Joseph Butterfield; Patrizia Bonadonna; Catherine Weiler; Stephen J Galli; Lawrence B Schwartz; Hanneke Oude Elberink; Anne Maitland; Theoharis Theoharides; Celalettin Ustun; Hans-Peter Horny; Alberto Orfao; Michael Deininger; Deepti Radia; Mohamad Jawhar; Hanneke Kluin-Nelemans; Dean D Metcalfe; Michel Arock; Wolfgang R Sperr; Peter Valent; Mariana Castells; Cem Akin
Journal:  J Allergy Clin Immunol       Date:  2021-03-11       Impact factor: 14.290

Review 7.  Mastocytosis: a mutated KIT receptor induced myeloproliferative disorder.

Authors:  Anindya Chatterjee; Joydeep Ghosh; Reuben Kapur
Journal:  Oncotarget       Date:  2015-07-30

8.  Phenotypic and genotypic characteristics of mastocytosis according to the age of onset.

Authors:  Fanny Lanternier; Annick Cohen-Akenine; Fabienne Palmerini; Frédéric Feger; Ying Yang; Yael Zermati; Stéphane Barète; Beatrix Sans; Cédric Baude; David Ghez; Felipe Suarez; Richard Delarue; Philippe Casassus; Christine Bodemer; Adeline Catteau; Frédérique Soppelsa; Katia Hanssens; Michel Arock; Hagay Sobol; Sylvie Fraitag; Danièle Canioni; Alain Moussy; Jean Marie Launay; Patrice Dubreuil; Olivier Hermine; Olivier Lortholary
Journal:  PLoS One       Date:  2008-04-09       Impact factor: 3.240

Review 9.  Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1.

Authors:  Ayalew Tefferi
Journal:  J Cell Mol Med       Date:  2008-10-23       Impact factor: 5.310

10.  Systemic mastocytosis with KIT V560G mutation presenting as recurrent episodes of vascular collapse: response to disodium cromoglycate and disease outcome.

Authors:  Iolanda Conde-Fernandes; Rita Sampaio; Filipa Moreno; José Palla-Garcia; Maria Dos Anjos Teixeira; Inês Freitas; Esmeralda Neves; Maria Jara-Acevedo; Luis Escribano; Margarida Lima
Journal:  Allergy Asthma Clin Immunol       Date:  2017-04-24       Impact factor: 3.406

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.